Amgen (AMGN) vs Johnson & Johnson (JNJ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Amgen (AMGN) has outperformed Johnson & Johnson (JNJ) over the past year, gaining 38.3% versus a gain of 35.2%. Over five years, AMGN leads with a +96.0% price change compared with +59.0% for JNJ. Johnson & Johnson is the larger company by market cap ($630.04 billion vs $224.29 billion), about 2.8 times the size, while Amgen is growing revenue faster (+10.0% vs +6.0%).
On valuation, Amgen trades at a lower forward P/E (16.9x vs 21.6x for Johnson & Johnson). Amgen offers the higher dividend yield (2.36% vs 2.00%). Johnson & Johnson converts more of its revenue into profit, with a net margin of 28.5% versus 21.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMGN | JNJ |
|---|---|---|
| Share price | $414.87 | $261.44 |
| Market cap | $224.29B | $630.04B |
| 1-day change | +1.82% | +1.93% |
| YTD return | +24.48% | +23.93% |
| 1-year return | +38.29% | +35.21% |
| 5-year return | +96.04% | +59.01% |
| P/E ratio (TTM) | 25.77 | 30.29 |
| Forward P/E | 16.94 | 21.60 |
| EPS (TTM) | $16.10 | $8.63 |
| Dividend yield | 2.36% | 2.00% |
| Annual dividend | $9.80 | $5.24 |
| Revenue (latest FY) | $36.75B | $94.19B |
| Revenue growth (YoY) | +9.95% | +6.05% |
| Net income (latest FY) | $7.71B | $26.80B |
| Gross margin | 67.25% | 67.88% |
| Operating margin | 24.71% | — |
| Net margin | 20.98% | 28.46% |
| 52-week high | $447.03 | $281.07 |
| 52-week low | $288.00 | $184.66 |
| Distance from 52-week high | -7.19% | -6.98% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -5.64% | +6.96% |
| Average volume | 2.74M | 7.01M |
| Shares outstanding | 540.63M | 2.41B |
| Employees | 31,500 | 138,200 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Johnson & Johnson is about 2.8 times larger than Amgen by market value ($630.04B vs $224.29B).
- Johnson & Johnson is more profitable, keeping 28.5 cents of every revenue dollar as net income versus 21.0 cents for Amgen.
About Amgen
AMGN stock →Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees
About Johnson & Johnson
JNJ stock →Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.
Health Care · Biotechnology: Pharmaceutical Preparations · 138,200 employees
AMGN vs JNJ FAQ
Which is bigger, Amgen or Johnson & Johnson?
Johnson & Johnson (JNJ) is larger, with a market capitalization of $630.04B compared with $224.29B for Amgen (AMGN).
Which stock has performed better over the past year, AMGN or JNJ?
AMGN returned +38.29% over the past 12 months, compared with +35.21% for JNJ (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMGN or JNJ?
AMGN has the lower trailing P/E at 25.8, versus 30.3 for JNJ. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Amgen or Johnson & Johnson?
Amgen has the higher yield at 2.36%, compared with 2.00% for Johnson & Johnson.
Are Amgen and Johnson & Johnson in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Amgen and Biotechnology: Pharmaceutical Preparations for Johnson & Johnson.